U.S. Biotech Stock News

CBIZ stock has surged in recent weeks and now trades very close to the US$55 per share price implied in Grant Thornton Advisors' agreed all cash acquisition, while the company's broader valuation checks still suggest the shares lean cheap rather than stretched. Over the past 5 years CBIZ has delivered a total return of about 70%, which points to meaningful long term value creation for shareholders compared to shorter term swings. The proposed US$5b all cash takeover by Grant Thornton...

Outlook Therapeutics stock has had a very weak run over the past five years, yet recent FDA approval for its lead drug has put fresh attention on whether the current US$1.00 share price is justified given the broader valuation checks. The share price has declined 97.9% over the past five years, which means long term holders have absorbed very heavy losses that set a low base for any future rerating. The recent FDA approval of LYTENAVA for wet age related macular degeneration can support...

Sunrun stock is trading around US$9.47 after a very steep 82.3% decline over the past 5 years, and the valuation checks send a mixed message about whether that reset has gone far enough. Over 5 years, Sunrun shareholders have seen the share price fall 82.3%. This puts the current valuation in the context of a long and painful reset rather than a short term swing. Future demand for residential solar and Sunrun's ability to turn that demand into steady cash flows can support the current price...

Markets are searching for companies that can keep growing even as inflation, energy costs and central bank decisions pull in different directions. The Fast Growing Stocks With High Insider Ownership screener focuses on businesses where analysts and management see room for further expansion, and where insiders have meaningful skin in the game. That combination can appeal if you want growth that is supported by both external research and internal conviction. In this article you will see 3...

Amneal Pharmaceuticals (AMRX) has drawn fresh attention after receiving U.S. Food and Drug Administration approval for additional strengths and vial sizes of its iohexol injection, which expands its radiographic contrast agent offering. See our latest analysis for Amneal Pharmaceuticals. The FDA approval arrives at a time when Amneal Pharmaceuticals’ share price momentum is strong, with a 30 day share price return of 10.47% and a year to date share price return of 50.87%, alongside a 1 year...

Tecnoglass stock has given shareholders a strong 150.1% return over the past 5 years, yet its recent slide and mixed valuation checks raise questions about how the current price stacks up against fundamentals. After a 40.9% decline over the past year and a year to date return that is down 13.8%, the focus now is whether the recent level around US$44.88 still offers value or mainly reflects past gains. Over 5 years Tecnoglass has returned 150.1%, which puts the recent share price weakness...

The latest Stellantis earnings update shows how quickly sentiment can swing when results and expectations do not line up. Net profit moved to €293 million in Q2 from a loss of €1.87 billion a year earlier, and adjusted operating income reached €773 million. However, the stock still fell as much as 8% on the day because the figure came in below the €914 million consensus. That kind of reaction can ripple across North American auto manufacturers. This article looks at 3 stocks exposed to that...

The Federal Trade Commission, Utah, and Los Angeles County filed a lawsuit against Hims & Hers Health (NYSE:HIMS) alleging unauthorized sharing of sensitive health data and deceptive billing practices. The complaint focuses on how the company handled patient information on its telehealth platform and how subscriptions and cancellations were billed and processed. The action highlights potential regulatory and reputational risks for Hims & Hers Health that investors may weigh when assessing...

The latest 1,000 point drop in the Dow after the Federal Reserve held interest rates steady has put value stocks back under the spotlight. With inflation still above target and U.S. oil prices near US$85 per barrel, many investors are taking a fresh look at large U.S. companies that already trade on lower price ratios and have some dividend history. This article focuses on three U.S. Large Cap Value Stocks from our screener that appear more directly exposed to the current rate and oil...

AAR Corp. recently reported fourth-quarter 2026 results showing sales of US$928 million and net income of US$50.7 million, alongside a completed US$107.54 million share repurchase program that retired 2,429,700 shares under its 2021 authorization. The company also filed an omnibus shelf registration covering multiple security types, giving it broad flexibility to raise capital after a year in which full-year earnings per share from continuing operations increased markedly. We’ll now examine...

Michael Kneeland, former CEO and current non executive chairman of United Rentals, has joined the board of directors of NYSE:XPO. Kneeland brings leadership experience in industrial services, equipment rental and logistics related businesses. This appointment marks a recent change in XPO's board composition and governance structure. XPO operates in freight transportation and logistics, a sector that depends heavily on operational efficiency, capital discipline and consistent service...

The Morning Bull - US Market Morning Update Thursday, Jul, 30 2026 US market stock futures are pointing slightly higher this morning, with E-mini S&P 500 contracts up about 0.3%, as investors weigh interest rate risks and energy prices. The US 10 year Treasury yield is steady ahead of the Federal Reserve meeting, where markets see roughly a one in three chance of a rate hike now and about 80% odds in September. That reflects concern that Middle East related oil price moves could keep...

Recent analyst reports on Atour Lifestyle Holdings (NasdaqGS:ATAT) have focused on upward revisions to earnings estimates and a Zacks Rank #1. This has drawn fresh attention to the stock within the leisure and recreation services sector. See our latest analysis for Atour Lifestyle Holdings. Atour Lifestyle Holdings has seen short term momentum pick up, with a 12.30% 7 day share price return and 9.31% 30 day share price return, although the share price is still down 11.39% year to date. The 3...

Novanta (NasdaqGS:NOVT) has completed its acquisition of Riverpoint Medical. The deal significantly increases Novanta's exposure to the medical consumables market. Management expects the transaction to approximately double recurring medical consumables revenue. Novanta focuses on precision photonics, vision and motion technologies used in medical and advanced industrial applications. With Riverpoint Medical now under its umbrella, the company gains a larger footprint in medical consumables,...

In late July 2026, SS&C Technologies Holdings, Inc. filed a US$779 million shelf registration for 10,000,000 common shares tied to an ESOP-related offering, shortly after reporting second-quarter 2026 revenue of US$1,695.7 million and net income of US$234.8 million, both higher than the prior year. The earnings release also showed higher basic and diluted earnings per share from continuing operations for both the quarter and first half of 2026, pointing to improved profitability alongside...

Eton Pharmaceuticals has submitted a Prior Approval Supplement to the FDA seeking to extend KHINDIVI’s hydrocortisone oral solution label to younger pediatric patients with adrenocortical insufficiency, beyond its current approval for those aged five and older. This move, backed by bioequivalence data versus ALKINDI SPRINKLE, could broaden treatment options in a rare disease population where Eton estimates about 10,000 U.S. pediatric patients. With KHINDIVI already the only FDA-approved...

Pentair stock has fallen sharply this year, yet the company still screens as undervalued on several key checks, including an intrinsic value estimate that sits well above the current share price. With sentiment hit by legal investigations and weaker trading in parts of the business, investors are weighing whether the current discount fairly reflects the risks now in play. Year to date, Pentair shares are down 36.9%, which means current holders have taken a sizeable hit and new investors are...

Fed Chair Kevin Warsh’s move to dial back forward guidance has left markets more data driven and, at times, more jumpy. When rate clues are harder to read, many investors start to focus on stocks that have shown relatively low price swings and steadier profiles. That is where a low volatility screener can help filter the chaos. This article looks at three stocks from that list that appear positively exposed to the current policy uncertainty and recent volatility in Treasury yields, and...

Adobe, ticker NasdaqGS:ADBE, has joined a new coalition to launch the Open Source AI Cybersecurity Alliance. The alliance focuses on open source collaboration to improve cybersecurity for artificial intelligence systems. This company initiative has not been widely covered in recent Adobe news as of July 2026. Adobe is best known for its creative and digital experience software, but its role in AI has been growing across products and services. Joining the Open Source AI Cybersecurity...

Northrop Grumman stock has delivered a 62.4% gain over the past five years, yet current valuation checks and intrinsic value estimates both point to the shares trading below what the underlying cash flows imply. With market sentiment still digesting mixed shorter term returns, the question is whether the current price fully reflects the company’s long term contract and earnings profile. Over five years, Northrop Grumman has returned 62.4%, which suggests long term holders have been rewarded...

Investors watching the latest Goldman Sachs tribunal decision on sex discrimination and unfair dismissal can see how quickly employment disputes turn into real financial and reputational costs. Human resources and employment law services sit close to this pressure point, from compliance advice to managing workplace disputes. When a £1.45mn award and critical findings on dismissal processes hit headlines, that can influence how companies think about risk management and where they spend on...

Gartner stock has had a tough run over the past year, yet current valuation checks suggest the share price may now sit below what its Discounted Cash Flow (DCF) and earnings multiple signals imply for intrinsic value. Over the past 12 months the share price has fallen 51.8%, which puts recent gains into context and raises the question of whether sentiment has moved further than the fundamentals. Recent headlines around Gartner's AI forecasts and its role in shaping spending on AI...

International Paper has delivered a 33.3% gain over the past three years, yet the stock still screens as undervalued on key valuation checks, which puts the recent price moves and containerboard news in sharp focus for investors. A 33.3% return over three years suggests International Paper has already rewarded patient shareholders. The question is whether the current price still leaves room for further upside or now embeds much of that progress. Recent containerboard price increase plans and...

Consumer lending stocks are feeling the strain as the Federal Reserve holds rates steady and energy driven inflation keeps household budgets tight. With borrowing costs elevated and credit cards, auto loans, and mortgages all putting pressure on consumers, some companies exposed to this news are facing tougher conditions than others. This article focuses on three consumer lending stocks that appear more vulnerable to the current rate and inflation backdrop. Each section explains how the...